WeSana Health
WeSana Health is a publicly traded Chicago-based life sciences company developing psilocybin-based therapeutic treatments targeted at brain injury indications, led by founder and CEO Daniel Carcillo. It acquired Toronto-based PsyTech in 2021 and is currently described as having no significant operations.
- Company typePublic
- Founded2020
- HeadquartersHomer Glen, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What WeSana Health does
WeSana Health is a publicly traded life sciences company focused on the development of psilocybin-based therapeutic treatments, with an explicit concentration on brain injury indications. The company was founded in 2020 and is led by Daniel Carcillo as founder and CEO, alongside co-founder Aristotle Loumis. It is headquartered in Chicago, Illinois, and trades on the OTC markets under WSNAF and on the CSE under WESA. The company is small, with a reported headcount band of 11-50 employees, and it serves a clinical/research end-market rather than a consumer product market.
The company's core product is a psychedelic-assisted therapy platform targeted at treating brain injuries, anchored by its July 2021 acquisition of the Toronto-based psychedelic therapy firm PsyTech for approximately $16.77 million. Beyond PsyTech, WeSana also acquired Debut Diamonds in May 2021, indicating opportunistic early capital deployment. Two private financings in 2021, totaling approximately $16.81 million, were led by Ambria Capital, The Conscious Fund, Gravitas Securities, JLS Fund, K2 & Associates, Negev Capital, and Sol Global Investments, providing the capital base for the public listing and the PsyTech integration.
Business model, pricing, distribution, customer base, and revenue mechanics are not publicly disclosed. No named customers, payer relationships, clinical partnerships, or recurring-revenue contracts are documented in the available data. Critically, as of March 2026 the company is described in third-party analysis as operating without significant operations, and the wesanahealth.com corporate domain appears to be non-functional or repurposed (returning Cloudflare access-denied responses and rendering unrelated Polish online-casino content). The financials presented in the input (revenue and loss figures in the billions) are implausible for a sub-50-employee clinical-stage psychedelic company and are treated as unreliable; the absence of any disclosed operating revenue remains the operative signal.
WeSana Health firmographics
Firmographics- Name
- WeSana Health
- Website
- https://wesanahealth.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- WeSana Health is a publicly traded Chicago-based life sciences company developing psilocybin-based therapeutic treatments targeted at brain injury indications, led by founder and CEO Daniel Carcillo. It acquired Toronto-based PsyTech in 2021 and is currently described as having no significant operations.
- Ownership category
- akta.pro rank
WeSana Health industry classification
Industry- Product category
- Psychedelic Medicine
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (621420)
- SIC
- Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Substance Use Disorder (SUD) Benefit Management (HLAEAHAF)
Keywords
Where WeSana Health is headquartered
LocationHeadquarters
- HQ city
- Homer Glen
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
WeSana Health business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
WeSana Health product offering
Product offeringCore offering
WeSana Health is a life sciences company developing psilocybin-based therapeutic treatments specifically targeting brain injuries. The company's core focus is advancing psychedelic-assisted therapy for neurological conditions, expanded through the 2021 acquisition of PsyTech, a Toronto-based psychedelic therapy firm. The company is described as having no significant operations as of March 2026.
Product overview
WeSana Health is a Chicago-based company focused on developing psychedelic therapy treatments for brain injuries. The company operates with a single therapeutic focus area, having expanded through the acquisition of a Toronto-based psychedelic therapy firm.
Differentiator
Problem solved
Functional benefit
Products and services
- Psychedelic Therapy for Brain Injuries
Companies that use WeSana Health
Customer profileIdeal customer profiles1 record
WeSana Health technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
WeSana Health partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Toronto-based psychedelic therapy firmcoreWesana Health announced the acquisition of a Toronto-based psychedelic therapy firm. This acquisition relates to Wesana's strategic focus on using psychedelics to treat brain injuries. The deal was part of the company's expansion into psychedelic therapy research and development for neurological conditions.
Scale indicators1 record
Recent moves5 records
Expansion highlights3 records
WeSana Health competitors and assessment
Company assessmentEmerging players
- Mydecine Innovations Group: Public (NEO: MYCO) psilocybin-therapy developer for nicotine addiction and PTSD; similar stage, capital base and psychedelic-medicine focus.
- BetterLife Pharma: Public (CSE: BETR) developer of psychedelic derivatives including BETR-001 (a non-hallucinogenic LSD analog); overlapping interest in non-classic psychedelic medicines for CNS indications.
- Seelos Therapeutics: Public (NASDAQ: SEEL) CNS-focused clinical-stage biotech; comparable small-cap clinical-stage structure even though its lead programmes are non-psychedelic.
Direct peers
- Compass Pathways: Public (NASDAQ: CMPS) developer of psilocybin therapy for treatment-resistant depression; the closest direct psychedelic-medicine peer by modality, regulatory pathway and public-market structure.
- MindMed: Public (NEO: MMED) psychedelic-medicine developer working on LSD and psilocybin-based therapies; comparable clinical-stage biotech structure and public-listing profile.
- atai Life Sciences: Public (NASDAQ: ATAI) clinical-stage biopharma focused on psychedelic and non-psychedelic therapies for mental health; comparable platform model spanning multiple psychedelic programmes.
- GH Research: Public (NASDAQ: GHRS) developer of psilocybin-based therapies for treatment-resistant depression; closely aligned modality and clinical-stage public-company structure.
- Cybin: Public (NYSE AMERICAN: CYBN) psychedelic-therapeutics developer with psilocybin and deuterated psychedelic programmes; comparable public psychedelic-biotech profile.
Broad incumbents
- Field Trip Health: Operated psychedelic-therapy clinics (and ran clinical development) across North America; broader incumbent in psychedelic-medicine delivery and adjacent to WeSana's clinical model.
- Numinus Wellness: Canadian psychedelic-therapy clinic operator and research collaborator; comparable North-American footprint and integration of clinical-research and clinical-delivery models.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
WeSana Health social profiles
Digital presenceWeSana Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
WeSana Health leadership team
Management profileNumber of profiles
Profiles2 records
WeSana Health subsidiaries and ownership
Company hierarchySubsidiaries1 record
WeSana Health funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WeSana Health M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WeSana Health
What does WeSana Health do?
WeSana Health is a life sciences company developing psilocybin-based therapeutic treatments specifically targeting brain injuries. The company's core focus is advancing psychedelic-assisted therapy for neurological conditions, expanded through the 2021 acquisition of PsyTech, a Toronto-based psychedelic therapy firm. The company is described as having no significant operations as of March 2026.
Is WeSana Health a public or private company?
WeSana Health is a public company. It is classified as public and is currently operating.
When was WeSana Health founded?
WeSana Health was founded in 2020. It employs 11 to 50 people.
Where is WeSana Health based?
WeSana Health is headquartered in Homer Glen, United States, in the North America region.
Who are WeSana Health's main competitors?
Emerging players on record are Mydecine Innovations Group, BetterLife Pharma and Seelos Therapeutics. Direct peers are Compass Pathways, MindMed, atai Life Sciences, GH Research and Cybin. Broad incumbents are Field Trip Health and Numinus Wellness.
Does WeSana Health have an API?
No public API is recorded for WeSana Health.
What industry is WeSana Health in?
WeSana Health's product category is Psychedelic Medicine. Its primary akta.pro industry code is HLAEAHAF, Substance Use Disorder (SUD) Benefit Management. Its NAICS code is 621420 and its SIC code is 8731.